Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GK Activator (2)
GK Activator · 7 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GK Activator (2) | DRUG | 25-200mg po bid for 20 weeks |
| Metformin | DRUG | As prescribed, in patients who were in study BM18249 |
| Placebo | DRUG | po bid |
| Glyburide | DRUG | 10-20mg po daily |
| Simvastatin | DRUG | 80mg po |
Inclusion Criteria: * adult patients, 18-75 years of age; * type 2 diabetes mellitus treated with one oral antihyperglycemic agent for \>=3 months prior to screening. Exclusion Criteria: * type 1 diabetes mellitus; * treatment with insulin, PPAR agonists or systemic corticosteroids during the 3 m...
GK Activator (2) is an investigational small molecule being studied for the treatment of type 2 diabetes mellitus. It is a metabolic therapy developed by Roche Holding AG. It has been evaluated in clinical trials in adults with type 2 diabetes, including drug-drug interaction studies and a dose-titration study.
GK Activator (2) is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the clinical program for this investigational type 2 diabetes therapy.
GK Activator (2) has reached Phase 2 in clinical development. A Phase 2 dose-titration study in patients with type 2 diabetes has been completed. The program also includes completed Phase 1 studies. It is an investigational drug and has not been approved by the FDA.
GK Activator (2) has been studied in seven completed clinical trials, including NCT00366379, a Phase 2 dose-titration study in type 2 diabetes, and Phase 1 drug-drug interaction studies NCT00388986 with glyburide and NCT00377442 with simvastatin. NCT00368368 evaluated the effect of renal impairment. No trials are currently active.
Yes, GK Activator (2) is also known as GK Activator. The two names refer to the same investigational small molecule developed by Roche Holding AG for type 2 diabetes mellitus.